New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.

Abstract : MPL (or thrombopoietin receptor, TPO-R) 515 mutations have recently been described in 5-10% of primitive myelofibrosis (PMF) cases as decisive oncogenic events capable of triggering the disease. Here we report additional mutations located in exon 10 of MPL in PMF patients. We investigated whether these new mutations also lead to cell transformation. MPL exon 10 was systematically sequenced in 100 PMF patients. Seven different mutations were found in eight patients. We introduced each MPL mutant in Ba/F3 cells to determine whether they correspond to gain-of-function mutations. Only MPL W515 mutations induced (1) Ba/F3 proliferation independently of growth factors, (2) tumorigenesis in nude mice, (3) spontaneous activation of JAK/STAT, RAS/MAPK and PI3K transduction pathways and (4) increased S phase of cell cycle. Similar to all other myeloproliferative disorder oncogenic events identified to date, these results demonstrate that only the detected MPL W515 mutations trigger spontaneous MPL activation leading to a G(1)/S transition activation. The other mutations are devoid of significant transforming activity but may synergize with JAK2 V617F or other not yet characterized molecular events.
Type de document :
Article dans une revue
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2008, 22 (8), pp.1557-66. 〈10.1038/leu.2008.137〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00410485
Contributeur : Jean-Paul Issartel <>
Soumis le : vendredi 21 août 2009 - 09:56:42
Dernière modification le : jeudi 15 mars 2018 - 10:12:30

Lien texte intégral

Identifiants

Citation

Ronan Chaligné, Carole Tonetti, Rodolphe Besancenot, Laurence Roy, Caroline Marty, et al.. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2008, 22 (8), pp.1557-66. 〈10.1038/leu.2008.137〉. 〈inserm-00410485〉

Partager

Métriques

Consultations de la notice

231